Sortera Bio Ltd

Based in the UK, Sortera Bio Ltd is a biotechnology company specializing in innovative drug discovery solutions, particularly through its proprietary Deep Screening technology. Sortera Bio Ltd focuses on advancing drug discovery methodologies. The company is headquartered in Cambridge, UK. It recently secured GBP 7.

5 mn in pre-seed funding on May, 2024, led by Cambridge Innovation Capital, with participation from AstraZeneca and BioNTech SE. This funding will be utilized to further develop its Deep Screening platform. Sortera Bio has completed one funding round to date. Sortera Bio specializes in innovative drug discovery solutions, focusing on its proprietary Deep Screening technology.

This platform generates extensive sequence-function datasets integral for advanced AI modeling. The technology meets the demand for high-quality, unbiased real-world data to enhance the design of novel biologics, particularly targeting challenging membrane proteins. The Deep Screening platform allows for thorough analysis of antibody libraries from various methods, and Sortera collaborates with key global partners in the biotechnology and pharmaceutical sectors, serving clients involved in biologics discovery across North America, Europe, and Asia-Pacific markets. Sortera Bio generates revenue primarily through partnerships and collaborations with major biotechnology and pharmaceutical companies.

The company offers access to its Deep Screening platform, facilitating long-term collaborations or project-based agreements. These partnerships often integrate Sortera's data-driven insights into clients' drug discovery processes, potentially leading to shared revenue models or milestone payments based on successful outcomes. Each pricing plan is customized to meet the specific needs of clients, highlighting the tailored nature of Sortera's services. In August 2025, Sortera Bio Ltd raised USD 7.

5 mn in funding to enhance its Deep Screening platform. The company plans to leverage these resources to bolster the development of its drug discovery technologies. While specific new product launches are not detailed, the funding is aimed at expanding Sortera's capabilities in drug discovery, potentially leading to the introduction of novel solutions. Additionally, Sortera Bio intends to explore expansion into new markets, focusing on scaling its operations and presence in North America and Asia-Pacific regions.